Cover Image
市场调查报告书

全球循环性癌细胞(CTC)及肿瘤干细胞(CSC)市场:产业规模·市场占有率与趋势·分析与预测

Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018

出版商 Transparency Market Research 商品编码 249547
出版日期 内容信息 英文 74 Pages
商品交期: 最快1-2个工作天内
价格
Back to Top
全球循环性癌细胞(CTC)及肿瘤干细胞(CSC)市场:产业规模·市场占有率与趋势·分析与预测 Circulating Tumor Cells (Ctcs) And Cancer Stem Cells (Cscs) Market - Global Industry Size, Market Share, Trends, Analysis, And Forecasts 2012 - 2018
出版日期: 2012年08月15日 内容信息: 英文 74 Pages
简介

循环性癌细胞技术(CTC),是可以在末梢血中分离的癌细胞的回复与分析的技术。CTC分析可以进行低侵袭时的转移的早期发现。CTC的分子分析可以进行计划且有效的治疗。从血液中除去CTC,可以抑制手术以及治疗后的转移。

本报告提供全球循环性癌细胞(CTC)及肿瘤干细胞(CSC)市场上技术,产业展望,市场规模,产业的成长率及市场趋势等分析,CTC及CSC市场上近几年的发展,市场参与企业的详细的简介,不同地区的市场分析等汇整,为您概述为以下内容。

第1章 简介

第2章 摘要整理

第3章 市场概要

  • 全球诊断市场概要
  • 诊断产业的SWOT分析
  • 癌症诊断市场现状
  • CTC及CSC概要
    • 市场现状
    • 未来的可能性
    • 成长机会
  • CTC及CSC研究的近几年的跃进
  • CTC及CSC市场促进因素
  • CTC及CSC市场阻碍要素
  • CTC及CSC市场机会

第4章 循环性癌细胞(CTC)

  • 循环性癌细胞是什么?
  • CTC发现的重要事项
  • CTC的生物学及特徵
  • CTC VS DTC
  • CTC浓缩法
  • 细胞搜索系统
  • CTC浓缩技术的优点与缺点
  • 诊断及检测的CTC的利用
  • CTC检测及分析相关预测
  • CTC及DTS的检测的改善
  • 全球癌症罹患率的增加

第5章 肿瘤干细胞(CSC)

  • 肿瘤干细胞(CSC)是什么?
  • 目前癌症诊断及治疗
  • 癌症的发病
  • 转移
  • 转移连锁
  • 转移最受影响的部位
  • CTC VS DTC
  • 有转移性疾病的患者的血液说明
  • CTC和CSC比较
  • EMT及EMT的3个层级
  • CSC的生物学
  • 干细胞标志物

第6章 竞争分析

  • CSC及CTC研究产品厂商的市场占有率
  • CSC研究焦点
  • 癌症死亡人数预测
  • 美国的新的癌症患者预测:各类型(男性·女性)
  • DTC检测的改善
  • 乳癌患者统计·数据
  • 原发性vs.转移性疾病的CTC的调查
  • 市场调查受访者层各不同地区分布
  • 肿瘤干细胞(CSC)标志物,恶性肿瘤及多重标志物简介
  • 市场分析·手法

第7章 地区分析

  • 北美
  • 欧洲
  • 亚太地区

第8章 企业简介

  • Johnson & Johnson
    • 企业概要
    • 成长策略
    • 近几年的开发
    • SWOT分析
  • Abbott Laboratories
  • Bristol-Myers Squibb (BMS)
  • Dexcom
  • Eli Lilly
  • GlaxoSmithKline
  • Glenmark Pharmaceuticals
  • Lupin
  • Roche
  • Sanofi

图表

目录

Circulating tumor cell technology is an enabling technology for recovery and analysis of separated cancer cells in the peripheral blood. CTC technology offers advantages like high sensitivity, high specificity, reproducible, repeatable, and non-invasive diagnostic assay for guiding treatment decision and improved patient triage. Circulatory tumor cells (CTC) are cancer cells that get separated from the primary tumor or its metastases that circulate in the peripheral blood. Metastasis the major cause of cancer deaths and CTC may constitute seeds from metastases and indicate the spread of diseases. The circulating tumor cells' analysis will allow early detection of metastasis when it is less invasive. Molecular characterization of CTC enables the treatment to be planned effectively. Removing CTC from the blood will limit metastases after surgery or therapy.

Molecular characterization is significant from the point of view of developing new methodologies for CTC detection, isolation, enumeration, and subsequent genetic or proteomic analysis. Advancement in medical technologies is allowing efficient removal of CTC from circulation and has therapeutic potential.

This research report analyzes the Circulating tumor cells and cancer stem cells market from a technical as well as business perspective, describing the overall market size, industry growth rate, and market trends. It gives an analysis of the recent developments in CTC and CSC markets and includes detailed profiles of top industry players along with Porter's five force analysis. The report also analyzes all the micro and macro factors essential for the existing market players and new entrants along.

Major regions covered under this research study are North America, Europe, the Asia-Pacific, and the Rest of the World.

Reasons to Buy this Report

  • This research report will provide a forward perspective on market issues affecting market growth rate
  • It will help in understanding the competitive environment and make accurate and informed business decisions to withstand competition
  • The report will provide pin-point analysis of changing competition dynamics to keep one ahead of competitors
  • It will provide an in-depth analysis of key product segments and robust product segments
  • The research report provides a seven-year forecast on business projections and segmental behavior

Table of Contents

1. Introduction

  • 1.1. Key Objectives
  • 1.2. Report Description
  • 1.3. Scope and Definitions
  • 1.4. Research Methodology

2. Executive Summary

3. Market Overview

  • 3.1. Overview of Global Diagnostic Market
  • 3.2. SWOT Analysis of Diagnostic Industry
  • 3.3. Current Status of the Cancer Diagnostic Market
  • 3.4. Overview of CTC and CSC
    • 3.4.1. Current Status of the Market
    • 3.4.2. Future Potential
    • 3.4.3. Growth Opportunities
  • 3.5. Recent Breakthrough in CTC and CSC Research
  • 3.6. Drivers for CTC and CSC Market
  • 3.7. Restraints for CTC and CSC Market
  • 3.8. Opportunities for CTC and CSC Market

4. Circulating Tumor Cells (CTC)

  • 4.1. What are Circulating Tumor Cells
  • 4.2. Important Milestone in CTC Discovery
  • 4.3. Biology and Characteristics of CTCs
  • 4.4. CTC for Cancer Diagnostics
  • 4.5. CTCs Vs DTCs
  • 4.6. CTC Enrichment Methods
    • 4.6.1. PCR-based Analysis
      • 4.6.1.1. RT-PCR
      • 4.6.1.2. RT-qPCR
    • 4.6.2. Cytometric Analysis
      • 4.6.2.1. CellSearch
      • 4.6.2.2. LSC
      • 4.6.2.3. FAST
      • 4.6.2.4. Flow cytometry
      • 4.6.2.5. CTC-Chip
      • 4.6.2.6. Elispot
      • 4.6.2.7. FISH
  • 4.7. Cell Search System
  • 4.8. Advantages and Disadvantages of CTC Enrichment Techniques
  • 4.9. CTC Utility in Diagnosis and Detection
  • 4.10. Predictions made on CTC detection and analysis
  • 4.11. Improvements in the detection of CTCs and DTCs
  • 4.12. Worldwide Growth in the Prevalence of Cancer

5. Cancer Stem Cells (CSC)

  • 5.1. What are Cancer Stem Cell (CSCs)
  • 5.2. Current Cancer Diagnostics and Therapy
  • 5.3. Developing Cancer
  • 5.4. Metastasis
  • 5.5. Metastatic Cascade
  • 5.6. Mostly Affected Sites by Metastasis
  • 5.7. CTCs Vs DTCs
  • 5.8. Blood Description of patient with metastatic disease
  • 5.9. Comparison between CTCS and CSCs
  • 5.10. EMT and Three Classes of EMT
  • 5.11. Biology of CSCs
  • 5.12. Stem Cells Markers

6. Competitive Analysis

  • 6.1. Market Shares of Various CSC and CTC Research Products vendors
  • 6.2. CSC Research Focus
  • 6.3. Estimated Cancer Deaths, 2011
  • 6.4. New cancer cases by type (male and female) in the U.S., 2012 (estimated)
  • 6.5. Improvement in CTC Detection
  • 6.6. Breast Cancer Statistics and Facts
  • 6.7. Study of CTCs for primary vs metastatic disease
  • 6.8. Geographic Distribution of Market Survey Respondent Pool
  • 6.9. Cancer stem cell (CSC) markers, malignancies and
  • multimarker profiles
  • 6.10. Market Analysis and Methodologies

7. Geographical Analysis

  • 7.1. North America
  • 7.2. Europe
  • 7.3. Asia Pacific

8. Company Profiles

  • 8.1. Johnson & Johnson
    • 8.1.1. Company Overview
    • 8.1.2. Growth Strategy
    • 8.1.3. Recent Development
    • 8.1.4. SWOT Analysis
  • 8.2. Abbott Laboratories
    • 8.2.1. Company Overview
    • 8.2.2. Growth Strategy
    • 8.2.3. Recent Development
    • 8.2.4. SWOT Analysis
  • 8.3. Bristol-Myers Squibb (BMS)
    • 8.3.1. Company Overview
    • 8.3.2. Growth Strategy
    • 8.3.3. Recent Development
    • 8.3.4. SWOT Analysis
  • 8.4. Dexcom
    • 8.4.1. Company Overview
    • 8.4.2. Growth Strategy
    • 8.4.3. Recent Development
    • 8.4.4. SWOT Analysis
  • 8.5. Eli Lilly
    • 8.5.1. Company Overview
    • 8.5.2. Growth Strategy
    • 8.5.3. Recent Development
    • 8.5.4. SWOT Analysis
  • 8.6. GlaxoSmithKline
    • 8.6.1. Company Overview
    • 8.6.2. Growth Strategy
    • 8.6.3. Recent Development
    • 8.6.4. SWOT Analysis
  • 8.7. Glenmark Pharmaceuticals
    • 8.7.1. Company Overview
    • 8.7.2. Growth Strategy
    • 8.7.3. Recent Development
    • 8.7.4. SWOT Analysis
  • 8.8. Lupin
    • 8.8.1. Company Overview
    • 8.8.2. Growth Strategy
    • 8.8.3. Recent Development
    • 8.8.4. SWOT Analysis
  • 8.9. Roche
    • 8.9.1. Company Overview
    • 8.9.2. Growth Strategy
    • 8.9.3. Recent Development
    • 8.9.4. SWOT Analysis
  • 8.10. Sanofi
    • 8.10.1. Company Overview
    • 8.10.2. Growth Strategy
    • 8.10.3. Recent Development
    • 8.10.4. SWOT Analysis
Back to Top